ATE123030T1 - Piperidin-derivate, ihre herstellung und ihre verwendung. - Google Patents

Piperidin-derivate, ihre herstellung und ihre verwendung.

Info

Publication number
ATE123030T1
ATE123030T1 AT90102913T AT90102913T ATE123030T1 AT E123030 T1 ATE123030 T1 AT E123030T1 AT 90102913 T AT90102913 T AT 90102913T AT 90102913 T AT90102913 T AT 90102913T AT E123030 T1 ATE123030 T1 AT E123030T1
Authority
AT
Austria
Prior art keywords
preparation
piperidine derivatives
piperidine
derivatives
Prior art date
Application number
AT90102913T
Other languages
English (en)
Inventor
Per Sauerberg
Preben H Olesen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK82589A external-priority patent/DK82589A/da
Priority claimed from DK231589A external-priority patent/DK231589D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE123030T1 publication Critical patent/ATE123030T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
AT90102913T 1989-02-22 1990-02-14 Piperidin-derivate, ihre herstellung und ihre verwendung. ATE123030T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK82589A DK82589A (da) 1989-02-22 1989-02-22 Piperidinforbindelser, deres fremstilling og anvendelse
DK231589A DK231589D0 (da) 1989-05-12 1989-05-12 Piperidinforbindelser og deres fremstilling og anvendelse

Publications (1)

Publication Number Publication Date
ATE123030T1 true ATE123030T1 (de) 1995-06-15

Family

ID=26064725

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90102913T ATE123030T1 (de) 1989-02-22 1990-02-14 Piperidin-derivate, ihre herstellung und ihre verwendung.

Country Status (22)

Country Link
US (5) US5043345A (de)
EP (2) EP0384288B1 (de)
JP (2) JP2921578B2 (de)
KR (1) KR0163763B1 (de)
CN (1) CN1028105C (de)
AR (1) AR247565A1 (de)
AT (1) ATE123030T1 (de)
AU (2) AU4999690A (de)
CA (2) CA2010578C (de)
DE (1) DE69019550T2 (de)
DK (1) DK0384288T3 (de)
ES (1) ES2072323T3 (de)
FI (2) FI95704C (de)
GR (1) GR3017062T3 (de)
HU (2) HU221623B1 (de)
IE (1) IE69672B1 (de)
IL (2) IL93352A (de)
NO (2) NO900831L (de)
NZ (1) NZ232615A (de)
PH (1) PH26465A (de)
PT (2) PT93242A (de)
RU (1) RU2042676C1 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0372125A1 (de) * 1988-11-08 1990-06-13 Akzo N.V. Oxazol und Thiazol-Derivate
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
US5264444A (en) * 1989-02-22 1993-11-23 Novo Nordisk A/S Piperidine compounds and use
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5260311A (en) * 1989-02-22 1993-11-09 Novo Nordisk A/S Piperidine compounds and their use
EP0459568A3 (en) * 1990-05-31 1992-09-30 Merck Sharp & Dohme Ltd. Substituted oxadiazoles and thiadiazoles for use in the treatment of glaucoma and novel compounds having such use
US5376668A (en) * 1990-08-21 1994-12-27 Novo Nordisk A/S Heterocyclic compounds
US5418240A (en) * 1990-08-21 1995-05-23 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
DK198590D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
USRE35822E (en) * 1990-08-21 1998-06-09 Novo Nordisk A/S Heterocyclic compounds
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5527813A (en) * 1990-08-21 1996-06-18 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
DK198490D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
AU656547B2 (en) * 1990-11-29 1995-02-09 Allergan, Inc. Use of pyridine derivatives in the treatment of ocular hypertension
EP0492903A1 (de) * 1990-12-21 1992-07-01 MERCK SHARP & DOHME LTD. Substituierte Pyrazine, Pyrimidine und Pyridazine zur Anwendung in der Behandlung von Glaukoma
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5641791A (en) * 1991-08-13 1997-06-24 Novo Nordisk A.S Heterocyclic compounds and their preparation and use
US5175166A (en) * 1991-08-27 1992-12-29 The University Of Toledo Muscarinic agonists
WO1993014089A1 (en) * 1992-01-13 1993-07-22 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US5244906A (en) * 1992-01-23 1993-09-14 Dowelanco Insect control with substituted oxadiazole and thiadiazole compounds
JPH08502508A (ja) * 1992-10-23 1996-03-19 メルク シヤープ エンド ドーム リミテツド ドーパミンレセプターサブタイプリガンド
CN1064681C (zh) * 1993-06-04 2001-04-18 诺沃-诺迪斯克有限公司 杂环化合物
US5753683A (en) * 1993-08-19 1998-05-19 Novo Nordisk A/S Antipsychotic method
PT734259E (pt) * 1993-08-19 2002-11-29 Novo Nordisk As Utilizacao de derivados de piperidina para o tratamento da esquizofrenia
IL112024A (en) * 1993-12-21 1999-07-14 Novo Nordisk As Pharmaceutical compositions comprising tetrahydropyridine derivatives substituted with oxadiazole or thiadiazole for treating gastrointestinal motility disorders
US5545638A (en) * 1993-12-21 1996-08-13 Novo Nordisk A/S Method of treating gastrointestinal motility disorders
US5929247A (en) * 1994-10-24 1999-07-27 Eli Lilly And Company Heterocyclic compounds and their preparation and use
US5998404A (en) 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5605908A (en) * 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
US5484794A (en) * 1994-11-09 1996-01-16 Eli Lilly And Company Method for treating anxiety
US5726193A (en) * 1994-10-31 1998-03-10 Eli Lilly And Company Method for treating anxiety
ATE191344T1 (de) * 1994-10-31 2000-04-15 Lilly Co Eli Tetrahydropyridin oxadiazol- oder -thiadiazol- verbindung zur behandlung von angstzuständen
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
US5612351A (en) * 1994-11-08 1997-03-18 Novo Nordisk A/S Method of treating urinary bladder dysfunctions
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
TW304167B (de) * 1995-01-30 1997-05-01 Lilly Co Eli
US5605701A (en) * 1995-02-17 1997-02-25 Eli Lilly And Company Transdermal formulation
US5852037A (en) 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
US5763457A (en) 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5998434A (en) * 1995-12-06 1999-12-07 Eli Lilly And Company Composition for treating pain
KR19990071977A (ko) * 1995-12-07 1999-09-27 피터 지. 스트링거 통증 치료 방법
GB9603755D0 (en) * 1996-02-22 1996-04-24 Pfizer Ltd Therapeutic agents
AU2738397A (en) * 1996-04-23 1997-11-12 Eli Lilly And Company Heterocyclic compounds
AU2991397A (en) * 1996-04-23 1997-11-12 Eli Lilly And Company Heterocyclic compounds
DE69724967D1 (de) * 1996-04-24 2003-10-23 Novo Nordisk As Heterozyklische verbindungen, ihre herstellung und ihre anwendung
EP0821959A3 (de) * 1996-08-01 1998-09-16 Eli Lilly And Company Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin zur Behandlung von Nikotin-Entzug
US6043258A (en) * 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
EP0821958A3 (de) * 1996-08-01 1998-07-08 Eli Lilly And Company Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von übermässiger Streitsucht
EP0821957A3 (de) * 1996-08-01 1998-04-22 Eli Lilly And Company Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von Drogenmissbrauch
EP0821956A1 (de) * 1996-08-01 1998-02-04 Eli Lilly And Company Verfahren zur Behandlung disruptiver Verhaltensstörungen
US6090829A (en) * 1996-08-01 2000-07-18 Eli Lilly And Company Method for treating excessive aggression
EP0821954A1 (de) * 1996-08-01 1998-02-04 Eli Lilly And Company Verfahren zur Behandlung von geistiger Zurückgebliebenheit
ES2171838T3 (es) * 1996-08-01 2002-09-16 Lilly Co Eli Uso de 3-(4-hexiloxi-1,2,5-tiadiazol-3-il)-1,2,5,6-tetrahidro-1-metilpiridina (xanomelina) para el tratamiento del trastorno bipolar.
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
AU4995797A (en) * 1996-10-23 1998-05-15 Eli Lilly And Company Method for treating dementia due to aids
DE69825605T2 (de) 1997-05-29 2005-09-15 H. Lundbeck A/S Behandlung der schizophrenie und der psychose
US6034108A (en) * 1997-07-28 2000-03-07 Eli Lilly And Company Method for treating mental retardation
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6096767A (en) * 1999-01-22 2000-08-01 The University Of Toledo Muscarinic receptor agonists
US6211204B1 (en) 1999-01-22 2001-04-03 University Of Toledo Muscarinic receptor agonists
US6376675B2 (en) * 1999-01-22 2002-04-23 The University Of Toledo Muscarinic receptor agonists
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258357A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
CN1821243B (zh) * 2005-08-30 2010-12-08 北京大学 取代的吡啶类m1受体激动剂、其制备方法及其用途
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20090012101A1 (en) * 2005-12-27 2009-01-08 University Of Toledo Mucarinic Agonists and Methods of Use Thereof
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
EP2021000A2 (de) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20110294835A1 (en) 2008-05-15 2011-12-01 The Board Of Trustees Of The University Of Illinois Muscarinic Agonists as Cognitive Enhancers
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
HUE044653T2 (hu) 2009-07-22 2019-11-28 PureTech Health LLC Készítmények olyan rendellenességek kezelésére, amelyek muszkarin-receptor aktiválással enyhíthetõk
JP5916746B2 (ja) 2010-11-15 2016-05-11 エージンバイオ， インコーポレイテッド 認知障害を処置するためのピリダジン誘導体、組成物、および方法
US9549928B2 (en) 2011-04-29 2017-01-24 The University Of Toledo Muscarinic agonists as enhancers of cognitive flexibility
CN106068256B (zh) 2013-12-20 2020-10-23 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法
EP3310785A4 (de) 2015-06-19 2018-12-26 Agenebio, Inc. Benzodiazepinderivate, zusammensetzungen und verfahren zur behandlung kognitiver beeinträchtigung
CA2996717A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
CA3104478A1 (en) 2018-06-19 2019-12-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CA3180743A1 (en) 2018-09-28 2020-04-02 Karuna Therapeutics, Inc. Composition comprising xanomeline and trospium for treating disorders ameliorated by muscarinic receptor activation
WO2021097427A1 (en) 2019-11-15 2021-05-20 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219646A (en) * 1986-03-27 1990-10-26 Merck Sharp & Dohme Oxadiazole derivatives of azacyclics for treating cns disorders
IL83275A (en) * 1986-09-08 1994-02-27 Novo Nordisk As Compounds 1,2, 4-Oxadiazolyl Pipridine Transformed, their preparation and pharmaceutical preparations containing them
US5017618A (en) * 1987-03-16 1991-05-21 University Of Florida Labile derivatives of ketone analogs of 3-substituted-1-alkylamino-2-propanols and their use as beta-adrenergic blockers
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
IL88156A (en) * 1987-11-13 1997-02-18 Novo Nordisk As Azacyclic compounds their preparation and pharmaceutical compositions containing them
NZ227841A (en) * 1988-02-12 1991-08-27 Merck Sharp & Dohme Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
DK162892C (da) * 1988-07-04 1992-05-11 Novo Nordisk As 1,2,5,6-tetrahydropyridinforbindelser, deres fremstilling og farmaceutiske praeparater indeholdende disse
US5260311A (en) * 1989-02-22 1993-11-09 Novo Nordisk A/S Piperidine compounds and their use
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
US5264444A (en) * 1989-02-22 1993-11-23 Novo Nordisk A/S Piperidine compounds and use
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198490D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5175166A (en) * 1991-08-27 1992-12-29 The University Of Toledo Muscarinic agonists

Also Published As

Publication number Publication date
FI95704B (fi) 1995-11-30
AU4999690A (en) 1990-08-30
KR910015569A (ko) 1991-09-30
IE900504L (en) 1990-08-22
PT93241B (pt) 1996-01-31
HUT58326A (en) 1992-02-28
US5043345A (en) 1991-08-27
JP2921578B2 (ja) 1999-07-19
EP0384285A3 (de) 1991-04-24
PT93242A (pt) 1990-08-31
NO900831L (no) 1990-08-23
FI900887A0 (fi) 1990-02-22
CA2010578A1 (en) 1990-08-22
HU900884D0 (en) 1990-05-28
CA2010578C (en) 2000-05-23
FI900886A0 (fi) 1990-02-22
EP0384288B1 (de) 1995-05-24
DK0384288T3 (da) 1995-10-02
FI95704C (fi) 1996-03-11
EP0384288A3 (de) 1991-04-10
AR247565A1 (es) 1995-01-31
KR0163763B1 (ko) 1998-12-01
US5284859A (en) 1994-02-08
JPH02255680A (ja) 1990-10-16
IE69672B1 (en) 1996-10-02
DE69019550D1 (de) 1995-06-29
DE69019550T2 (de) 1995-10-05
EP0384288A2 (de) 1990-08-29
US5559138A (en) 1996-09-24
EP0384285A2 (de) 1990-08-29
GR3017062T3 (en) 1995-11-30
NO900830L (no) 1990-08-23
NO900830D0 (no) 1990-02-21
IL93423A0 (en) 1990-11-29
PT93241A (pt) 1990-08-31
CN1045104A (zh) 1990-09-05
HU221623B1 (hu) 2002-12-28
US5712297A (en) 1998-01-27
NO179639C (no) 1996-11-20
NO900831D0 (no) 1990-02-21
US5041455A (en) 1991-08-20
IL93352A (en) 1994-08-26
JPH02255679A (ja) 1990-10-16
IL93352A0 (en) 1990-11-29
NZ232615A (en) 1992-06-25
ES2072323T3 (es) 1995-07-16
HU211705A9 (en) 1995-12-28
PH26465A (en) 1992-07-27
AU629302B2 (en) 1992-10-01
CN1028105C (zh) 1995-04-05
CA2010579A1 (en) 1990-08-22
NO179639B (no) 1996-08-12
AU4999790A (en) 1990-08-30
RU2042676C1 (ru) 1995-08-27

Similar Documents

Publication Publication Date Title
DE69019550T2 (de) Piperidin-Derivate, ihre Herstellung und ihre Verwendung.
DE3885534D1 (de) Arylphosphorderivate, ihre Herstellung und Verwendung.
ATE89560T1 (de) Makrolid-derivate, ihre herstellung und ihre verwendung.
ATE258549T1 (de) Oxazolidindion-derivate, ihre herstellung und verwendung
DE69008454D1 (de) Nitrolsothiolderivate, ihre Herstellung und Verwendung.
DE68910853D1 (de) Triazol-Derivate, ihre Herstellung und ihre Verwendung als Fungizide.
DE3777366D1 (de) 2,3-dihydro-cumaron-derivate, ihre herstellung und verwendung.
DE3788709D1 (de) Piperidin-Derivate, ihre Herstellung und Anwendung.
ATA3589A (de) Neue isochinolinderivate, ihre herstellung und ihre verwendung
DE69027170T2 (de) Uracilderivate, ihre Herstellung und ihre Verwendung
DE59208576D1 (de) 3-Isoxazolylphenylverbindungen, ihre Herstellung und ihre Verwendung
DE3784602T2 (de) Inonos-derivate, ihre herstellung und verwendung.
DE3883297D1 (de) Phenolderivate, ihre herstellung und verwendung.
DE68908389T2 (de) Amidofluoroverbindungen, ihre herstellung und ihre verwendung.
DE68919259T2 (de) N-Phenylimide, ihre Herstellung und Verwendung.
DE59501950D1 (de) Isolongifolanol-Derivate, ihre Herstellung und ihre Verwendung
DE3770299D1 (de) 1,2,4-triazinonderivate, ihre herstellung und verwendung.
DE69008085D1 (de) Oxetanocinderivate, ihre Salze und ihre Verwendung.
DE69015602D1 (de) Oxadiazolinon-Derivat, seine Herstellung und seine Verwendung.
DE68910893T2 (de) Alkenyltetrazole Derivate, ihre Herstellung und ihre Verwendung.
ATE104956T1 (de) Nitrolsothiolderivate, ihre herstellung und verwendung.
DE59003728D1 (de) 4-Aryl-2-halogenimidazol-5-carbonsäureester, ihre Herstellung und Verwendung.
ATE63905T1 (de) 1,2,4-triazinonderivate, ihre herstellung und verwendung.
ATE73448T1 (de) 2,3-dihydro-cumaron-derivate, ihre herstellung und verwendung.
PT85600A (de) 3-brom-2,6-dimethoxibenzamide ihre herstellung und verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee